MS-N147 · Cancer control · Experimental claim · Safety · Human evidence · Appraised 26 October 2026

Do antineoplastons—laboratory-made mixtures related to compounds found in urine and blood—treat cancer?

Evidence at a glance

• Evidence label: No randomized controlled evidence; not FDA approved; published evidence is uncontrolled
• Benefit: Phase I/II reports and case series do not establish that antineoplastons improve tumor response or survival.
• Certainty: Low for efficacy because independent randomized trials are absent and many reports come from the originating clinic.
• Risk: Mild to severe toxicity has been reported, including confusion, seizures, brain swelling, abnormal electrolytes and cardiovascular effects.

What was studied

Intervention: Antineoplastons are laboratory-made chemical compounds, often amino-acid and peptide derivatives, administered by mouth or injection. Formulations and dosing schedules have varied.

Human evidence: NCI PDQ identifies phase I studies, phase II studies and case reports across brain and other cancers but no published phase III randomized controlled trial. Some participants also received standard treatment, making attribution difficult.

What the evidence found

NCI states that no randomized controlled antineoplaston trials have been published in peer-reviewed journals. Uncontrolled responses cannot determine how many similar patients did not respond, whether imaging criteria were applied consistently or whether standard treatment caused the change.

Reported adverse effects include anemia, abnormal calcium, high blood pressure, irregular heartbeat, nausea and vomiting, edema, confusion and seizures. The most severe events in a brain-tumor phase II study included somnolence, confusion, seizures and swelling near the brain.

Antineoplastons are not FDA approved for prevention or treatment of any disease. Trial registration or permission to conduct an investigational study is not evidence of efficacy or approval.

How to interpret it

The central question is not whether isolated responses were reported; it is whether a controlled, independently reproducible study shows better outcomes than an appropriate comparator. That evidence is absent.

People with aggressive tumors are especially vulnerable to treatment delay and to fluid, sodium or neurologic complications.

Practical safety context

Do not obtain antineoplastons outside a properly authorized clinical trial, and do not postpone established treatment. Urgent evaluation is needed for seizure, worsening headache, confusion, weakness, vomiting, severe sleepiness or sudden blood-pressure or rhythm changes.

Questions for the care team

• Is there a peer-reviewed randomized comparison for this exact tumor type and formulation?
• Is the trial registered, currently authorized and overseen by an independent ethics board and safety monitor?
• How are sodium, fluid balance, neurologic status and imaging response monitored?

Funding and conflicts

Much of the published clinical literature originated from the developer’s clinic. NCI PDQ is an independent evidence summary, but its antineoplaston page notes that recent research is weak or absent and is retained for reference. Funding and conflicts vary across individual reports and should be checked study by study.

Sources

• NCI PDQ: Antineoplastons
• NCI PDQ full text via NCBI Bookshelf
• PDQ bibliographic record (PMID 26389445)

Last literature search: 26 October 2026. Record appraisal: 26 October 2026. This page is educational and does not replace individualized medical advice. Laboratory effects, biomarkers, symptom changes or an uncontrolled response must not be interpreted as proof of tumor control, delayed recurrence or longer survival.